Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick C Gedeon

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Plos One|August 1, 2020
GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibodyPatrick C Gedeon, Michael A Streicker, Teilo H Schaller, et al.
Expert Review of Clinical Pharmacology|August 10, 2013
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastomaPatrick C Gedeon, Bryan D Choi, Tiffany R Hodges, et al.
Video-Assisted Thoracic Surgery|September 15, 2023
Anatomy of the lung revisited by 3D-CT imagingSeshiru Nakazawa, Toshiteru Nagashima, Natsuko Kawatani, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|September 24, 2013
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human gliomaBryan D Choi, Carter M Suryadevara, Patrick C Gedeon, et al.
Journal of Immunological Methods|June 29, 2013
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesisBryan D Choi, Patrick C Gedeon, Chien-Tsun Kuan, et al.
Neuro-Oncology|October 25, 2014
Epidermal growth factor receptor and variant III targeted immunotherapyKendra L Congdon, Patrick C Gedeon, Carter M Suryadevara, et al.
Oncoimmunology|July 9, 2015
Are BiTEs the "missing link" in cancer therapy?Carter M Suryadevara, Patrick C Gedeon, Luis Sanchez-Perez, et al.
Antibodies (Basel, Switzerland)|November 21, 2023
The Role of Antibody-Based Therapies in Neuro-OncologyRishab Ramapriyan, Jing Sun, Annabel Curry, et al.
Expert Review of Clinical Pharmacology|September 1, 2020
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlookPatrick C Gedeon, Cosette D Champion, Kristen E Rhodin, et al.
Cancer Immunology Research|February 27, 2014
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibodyBryan D Choi, Patrick C Gedeon, James E Herndon, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Plos One|August 1, 2020
GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibodyPatrick C Gedeon, Michael A Streicker, Teilo H Schaller, et al.
Expert Review of Clinical Pharmacology|August 10, 2013
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastomaPatrick C Gedeon, Bryan D Choi, Tiffany R Hodges, et al.
Video-Assisted Thoracic Surgery|September 15, 2023
Anatomy of the lung revisited by 3D-CT imagingSeshiru Nakazawa, Toshiteru Nagashima, Natsuko Kawatani, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|September 24, 2013
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human gliomaBryan D Choi, Carter M Suryadevara, Patrick C Gedeon, et al.
Journal of Immunological Methods|June 29, 2013
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesisBryan D Choi, Patrick C Gedeon, Chien-Tsun Kuan, et al.
Neuro-Oncology|October 25, 2014
Epidermal growth factor receptor and variant III targeted immunotherapyKendra L Congdon, Patrick C Gedeon, Carter M Suryadevara, et al.
Oncoimmunology|July 9, 2015
Are BiTEs the "missing link" in cancer therapy?Carter M Suryadevara, Patrick C Gedeon, Luis Sanchez-Perez, et al.
Antibodies (Basel, Switzerland)|November 21, 2023
The Role of Antibody-Based Therapies in Neuro-OncologyRishab Ramapriyan, Jing Sun, Annabel Curry, et al.
Expert Review of Clinical Pharmacology|September 1, 2020
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlookPatrick C Gedeon, Cosette D Champion, Kristen E Rhodin, et al.
Cancer Immunology Research|February 27, 2014
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibodyBryan D Choi, Patrick C Gedeon, James E Herndon, et al.
Pageof 3